Press Releases

Press Releases

Press Releases

Date Title and Summary Additional Formats
Apr 30, 2019
Genomic Health to Announce First Quarter 2019 Financial Results and Host Conference Call on Tuesday, May 7, 2019
REDWOOD CITY, Calif. , April 30, 2019 /PRNewswire/ --  Genomic Health, Inc.  (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, May 7 at 4:30 p.m. Eastern Time to discuss its first quarter 2019 financial results.
Mar 25, 2019
New Long-term Outcomes Data Presented at St. Gallen International Breast Cancer Conference Reinforce TAILORx Treatment Paradigm and Standard of Care Use for Oncotype DX Breast Recurrence Score® Test
Importance of tailoring chemotherapy use and differences between tests acknowledged by leading international breast cancer specialists REDWOOD CITY, Calif. , March 25, 2019 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that new data presented at the 16th St.
Feb 20, 2019
Genomic Health Reports Record 2018 Fourth Quarter and Year-end Financial Results and Provides 2019 Financial Guidance
Delivered $394.1M in Full-year Revenue and Growth of 18 Percent for the Full Year Reported Full-year Profit of $25.7M on a GAAP Basis and $39.7M on a Non-GAAP Basis Achieved 14th Consecutive Quarter of Improved Non-GAAP Profitability Guides to 14% Revenue Growth and 50% Non-GAAP Net Income Growth
Feb 13, 2019
Genomic Health to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on Wednesday, February 20, 2019
REDWOOD CITY, Calif. , Feb. 13, 2019 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Wednesday, February 20 at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end 2018 financial results.
Feb 05, 2019
Oncotype DX® Genomic Prostate Score® Established as First Genomic Test with Prospective Validation for Predicting Adverse Pathology in Newly Diagnosed Patients
Results, Published in Urology, Represent First Prospective Validation of Critical Endpoint to Identify Patients for Active Surveillance REDWOOD CITY, Calif. , Feb. 5, 2019 /PRNewswire/ --  Genomic Health, Inc . (Nasdaq: GHDX) today announced the publication of results from a multi-center,
Jan 07, 2019
Genomic Health Marks More than 1 Million Patients Worldwide Who Have Benefited from Oncotype DX Testing in Personalizing Cancer Treatment Decisions to Improve Outcomes
Pioneering Precision Medicine While Saving Healthcare Costs REDWOOD CITY, Calif. , Jan. 7, 2019 /PRNewswire/ --  Genomic Health , Inc.  (NASDAQ: GHDX) today announced that, in collaboration with physicians around the world, it has delivered more than 1 million Oncotype DX ® tests to cancer patients
Dec 19, 2018
NICE Expands Recommendation for the Oncotype DX Breast Recurrence Score® Test to More Patients with Early-Stage Breast Cancer Within the United Kingdom
- Only test recommended based on its ability to predict chemotherapy benefit - Recommendation expanded to include patients with micrometastatic disease REDWOOD CITY, Calif. , Dec. 19, 2018 /PRNewswire/ --  Genomic Health, Inc. (NASDAQ: GHDX) today announced that the National Institute for Health
Dec 18, 2018
Genomic Health to Present at the 37th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif. , Dec. 18, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that Kim Popovits , chairman of the board, chief executive officer and president, will present at the 37 th Annual J.P. Morgan Healthcare Conference at the Westin St.
Dec 10, 2018
Multiple Oncotype DX Study Presentations at the 2018 San Antonio Breast Cancer Symposium Reinforce Real-world Value of the Oncotype DX Breast Recurrence Score® Test in Patients Regardless of Age or Race
REDWOOD CITY, Calif. , Dec. 10, 2018 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced results from multiple Oncotype DX Breast Recurrence Score ® (RS) presentations at the 2018 San Antonio Breast Cancer Symposium ® (SABCS), reinforcing the value of the Oncotype DX ® test in
Dec 03, 2018
Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla™ Oncotype DX® Genomic Prostate Score® Test
REDWOOD CITY, Calif. and MECHELEN, Belgium , Dec. 3, 2018 /PRNewswire/ --  Genomic Health , Inc. (NASDAQ: GHDX), the world's leading provider of genomic-based diagnostic tests and Biocartis Group NV, an innovative molecular diagnostics company (Euronext Brussels: BCART), today announced they have